Welcome! We ship worldwide.

Service and Support: 1-855-955-1114 / 1-587-271-1114

Clinical Reference // Indications & Dosage


hardy nutritionals indications and dosage

3.1 Indications

Daily Essential Nutrients is indicated for the treatment of mood, anxiety, and behavioral symptoms. 

Significant evidence exists to indicate that a wide range of mood, anxiety, and behavioral symptoms can result from inadequate intake of vitamins and minerals and/or poor nutrient status and that broad-spectrum micronutrient interventions substantially similar to DEN can significantly alleviate these symptoms.(19)

3.2 Dosage

In general, the recommended therapeutic dose of Daily Essential Nutrients is 4 capsules three times daily with food. One level scoop of Daily Essential Nutrients Powder is equivalent to 4 DEN capsules.

In published research, both adults and children have responded well when broad-spectrum micronutrient formulas substantially similar to Daily Essential Nutrients have been administered at levels comparable to this therapeutic dosage (see Appendix A).

Based on clinical experience, young children (generally ages 2-5) diagnosed with psychiatric conditions may require lower doses of Daily Essential Nutrients (often about 4-8 capsules/day).

Maintenance requires an adequate dose of Daily Essential Nutrients that preserves symptom remission. Optimal maintenance dosage will vary with individual needs.

For additional Daily Essential Nutrients dosage considerations, including initial dosage titration, see 7 Treatment Guidelines.



3.2.1 Biological safety data
Biological safety data from 144 children and adults were available from eight datasets of broad-spectrum micronutrient formulas substantially similar to DEN which were administered at comparable therapeutic dosages. In these reports, there was not a single reported occurrence of a clinically meaningful negative outcome/effect or an abnormal blood test that could be attributed to toxicity.(1)

Testing included routine blood samples, heart rate and blood pressure measurements. One dataset included a full laboratory panel at baseline, completion, and at the end of open label extension. In addition, a smaller safety panel (hematology, potassium, calcium, alanine aminotransaminase, creatinine and estimated glomerular filtration rate (eGFR)) was performed every two weeks during each study phase.

For each dataset, no significant changes were noted and all values remained within normal clinical reference ranges.(1)